Welcome to our dedicated page for Sonoma Pharmaceu SEC filings (Ticker: SNOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sonoma Pharmaceuticals filings document the regulatory record for a Nasdaq-listed healthcare company with common stock trading under SNOA. Its disclosures include Securities Act registration statements, current reports on material events, proxy materials for shareholder voting matters, and common-stock and capital-structure information.
Recent filings cover material agreements involving Microcyn technology-based products, governance and executive or director changes, investor presentation materials, and proxy items related to corporate organization and stockholder approval mechanics. Registration statements and amendments describe offered securities, reporting-company status and related disclosure controls, while 8-K reports record definitive agreements, leadership matters and other company events affecting Sonoma’s operations and governance.
Sonoma Pharmaceuticals updated investors on its at-the-market stock offering program with Ladenburg Thalmann. The company originally registered up to $2,070,463 of common stock under a Form S-3 shelf and related prospectus supplement. From September 26, 2025 through June 18, 2026, it sold 173,073 shares for an aggregate purchase price of $574,633 under this agreement. As of June 18, 2026, the amount of common stock it may offer pursuant to General Instruction I.B.6 of Form S-3 has increased to an aggregate offering price of $3,641,703, and Sonoma filed a supplement to the prospectus supplement to increase the aggregate offering price to this level, including the $1,495,830 shares of common stock that were previously registered and not sold to date.
Sonoma Pharmaceuticals amends its prospectus supplement to increase its at-the-market offering capacity to $3,641,703. The company will continue to sell common stock through Ladenburg Thalmann under an ATM agreement; prior sales under the prospectus supplement totaled $574,633 from 173,073 shares.
The supplement replaces the previously stated maximum aggregate offering price of $2,070,463 with $3,641,703. As of June 18, 2026, the public float was reported at $12,649,011, calculated on 4,785,801 shares outstanding and a closing price of $2.65 per share on April 20, 2026. The filing notes the company may not sell more than one-third of its public float in any 12-month period under General Instruction I.B.6 of Form S-3.
Sonoma Pharmaceuticals’ annual report describes a global specialty medical-device business built on stabilized hypochlorous acid (HOCl) for dermatology, wound care, eye care, podiatry, animal health and surface disinfection. The company sells in over 55 countries, manufactures in Mexico, and emphasizes partnering with distributors rather than building large direct sales forces.
For the year ended March 31, 2026, research and development expenses were $2,271,000, up from $1,814,000 in 2025, as Sonoma advanced new HOCl products and regulatory clearances. About 71% of 2026 revenue came from outside the United States, and customer C represented 15% of net revenues, highlighting both international reach and customer concentration. The company notes significant intercompany loans to its Mexican subsidiary and related tax and withholding exposures, and it operates under extensive U.S., EU and Mexican medical device and healthcare regulations, including 22 FDA 510(k) clearances and updated CE certificates under the EU Medical Devices Regulation.
Sonoma Pharmaceuticals, Inc. is asking stockholders to approve a reincorporation from Delaware to Nevada and authority to adjourn the special meeting if needed. The board cites eliminating roughly $200,000 in annual Delaware franchise taxes, replacing them with Nevada fees of about $650, and broader director and officer liability protections.
The move would not change existing ownership, as each Delaware common share would convert into one Nevada common share. Stockholders of record on April 28, 2026, when 3,473,554 common shares were outstanding, may vote in person or by proxy at the June 24, 2026 special meeting.
Sonoma Pharmaceuticals completed a public offering of units combining common stock or pre-funded warrants with common stock purchase warrants, raising new capital for the business. The deal was underwritten by Dawson James Securities.
The company sold 2,962,962 units at $1.35 per unit, with each unit including one share of common stock or a pre-funded warrant and one warrant to buy a share at $1.35. Including full use of the over-allotment option, Sonoma issued 1,650,716 common shares, 1,312,247 pre-funded warrants and 3,407,404 warrants. Net proceeds are expected to be about $3.5 million, which Sonoma plans to use for general corporate purposes and working capital.
Sonoma Pharmaceuticals, Inc. is offering up to 2,962,962 units, each consisting of one share of common stock (or a Pre-Funded Warrant in lieu thereof) and one common warrant, at a public offering price of $1.35 per unit, in a firm commitment underwriting for gross proceeds of approximately $4.0 million. Each common warrant is exercisable immediately at $1.35 and expires five years after issuance. The offering includes Pre-Funded Warrants to permit purchasers to avoid exceeding 4.99% (or, at election, 9.99%) beneficial ownership limits; Pre-Funded Warrants have an exercise price of $0.0001 and no expiration date. The underwriters have a 45-day option to purchase up to 444,444 additional shares/warrants. Net proceeds are intended for working capital and general corporate purposes. The company’s common stock trades on Nasdaq under the symbol SNOA.
Sonoma Pharmaceuticals, Inc. is asking shareholders to approve a conversion of its state of incorporation from Delaware to Nevada and a related adjournment proposal if additional solicitation is needed. The proposal would effect a statutory conversion, preserve existing equity (one-for-one share conversion), and carry anticipated changes to governing law, director liability provisions, and certain corporate procedures.
The Board states the move would eliminate the Company’s Delaware franchise tax (approximately $200,000 for tax year 2025), replace it with Nevada statutory fees, and adopt Nevada articles and bylaws that change director removal, indemnification, quorum and other corporate governance rules. The Special Meeting is scheduled for June 24, 2026.
Sonoma Pharmaceuticals, Inc. is registering up to 2,024,291 units in a firm commitment public offering, each unit consisting of one share of common stock (or a Pre-Funded Warrant) and one common warrant. The deal targets approximately $5 million in gross proceeds at an assumed price of $2.47 per unit.
The company is also registering up to 2,125,506 shares of common stock issuable upon exercise of the Pre-Funded Warrants, common warrants and Underwriter’s Warrants. Common stock outstanding would increase from 1,741,424 shares to about 3,847,129 shares, assuming all Pre-Funded Warrants are exercised and none of the warrants are exercised.
Pre-Funded Warrants carry a de minimis $0.0001 exercise price and no expiration, while common warrants are exercisable immediately for five years at a price equal to 100% of the final public offering price. A 4.99% (or, at purchaser election, 9.99%) beneficial ownership cap applies to warrant exercises. Net proceeds of about $4.48 million are earmarked for working capital and general corporate purposes.
Sonoma Pharmaceuticals is planning a firm-commitment underwritten public offering of units to raise approximately $5 million. Each unit includes one share of common stock (or a pre-funded warrant) plus a common warrant to buy one additional share, with warrant exercise prices tied to the final public offering price.
Pre-funded warrants will carry a nominal $0.0001 exercise price and no expiration, with 4.99% or 9.99% beneficial ownership limits, while common warrants will be immediately exercisable and expire five years after issuance. Based on an assumed price of $2.47 per unit, Sonoma estimates net proceeds of about $4.48 million, after a 7.5% underwriting discount and offering expenses.
The company expects to use the cash for working capital and general corporate purposes, including product launches and potential R&D and capital spending. The example capital structure shows pro forma net tangible book value per share rising modestly, but new investors would experience dilution versus the assumed offering price.